Atropine Dosing for Symptomatic Bradycardia in Adults
For adults with symptomatic bradycardia, administer atropine 0.5 mg intravenously, repeated every 5 minutes as needed, up to a maximum total dose of 2.0 mg (or 2.5 mg in asystole). This represents the consensus dosing protocol from multiple ACC/AHA guidelines and FDA labeling 1, 2, 1, 3.
Initial Dosing Protocol
- Starting dose: 0.5 mg IV push
- Repeat interval: Every 5 minutes if bradycardia persists
- Maximum total dose: 2.0 mg for symptomatic bradycardia
- Peak effect: Within 3 minutes of administration 2
The 2019 ACC/AHA/HRS bradycardia guidelines confirm that atropine at dosages of 0.5 to 2 mg usually enhances automaticity in sinus bradycardia 4. The FDA label specifies titration based on heart rate, PR interval, blood pressure, and symptoms 3.
Critical Dosing Considerations
Never administer doses less than 0.5 mg, as this can paradoxically worsen bradycardia through central vagal stimulation or peripheral parasympathomimetic effects 2. This paradoxical response is well-documented and represents a common pitfall in atropine administration.
In patients with coronary artery disease, limit the total cumulative dose to 0.03-0.04 mg/kg to minimize risk of increased myocardial oxygen demand and potential ischemia 3. The guidelines emphasize using atropine cautiously in acute MI settings, titrating to achieve a minimally effective heart rate (approximately 60 bpm) rather than aggressive rate acceleration 1.
Special Circumstances
Asystole
For ventricular asystole specifically, the recommended dose is 1 mg IV, repeated every 5 minutes during CPR if asystole persists, with a maximum cumulative dose of 2.5 mg over 2.5 hours 2.
Type of Bradycardia
Atropine is most effective for:
- Symptomatic sinus bradycardia (heart rate <50 bpm with hypotension, ischemia, or escape ventricular arrhythmias) 1
- AV block at the AV nodal level (second-degree type I or third-degree with narrow-complex escape rhythm) 1
Atropine is contraindicated or ineffective for infranodal AV block (type II second-degree or third-degree with wide-complex escape rhythm), as it may paradoxically worsen the block by increasing sinus rate without improving conduction 1, 2, 1.
Clinical Evidence and Efficacy
Real-world data demonstrates variable but meaningful efficacy. A prehospital study of 131 patients with hemodynamically unstable bradycardia or AV block found that 47.3% had either partial (19.8%) or complete (27.5%) response to atropine, while 49.6% had no response and 2.3% had adverse effects 5. Patients with simple bradycardia responded better than those with AV block, requiring fewer total doses.
Research confirms atropine effectively treats symptomatic sinus bradycardia in acute MI, reducing premature ventricular contractions in 87% of patients and normalizing blood pressure in 88% of hypotensive patients 6. However, adverse effects (ventricular tachycardia/fibrillation, sustained sinus tachycardia, increased PVCs) correlated with initial doses ≥1.0 mg or cumulative doses exceeding 2.5 mg over 2.5 hours 6.
Monitoring and Safety
Monitor continuously for:
- Excessive tachycardia that may increase myocardial oxygen demand
- Ventricular arrhythmias (rare but serious complication)
- CNS effects with repeated dosing (hallucinations, fever)
- Worsening ischemia in acute coronary syndromes 2
When Atropine Fails
If bradycardia remains symptomatic despite maximum atropine dosing, proceed immediately to transcutaneous pacing or consider dopamine infusion (5-20 mcg/kg/min) 1, 4. Do not continue escalating atropine beyond recommended maximum doses, as this increases toxicity risk without additional benefit.